Document is current
Any future updates will be listed below
-
Authors
Mehta, Rohtesh S.
Aljawai, Yosra M.
Kebriaei, Partow
Cao, Kai
Zou, Jun
Carmazzi, Yudith
Rondon, Gabriela
Oran, Betul
Popat, Uday
Rezvani, Katayoun
Champlin, Richard E.
Shpall, Elizabeth J.
- License Information
-
More Information
Article History
Received: 4 August 2025
Accepted: 14 January 2026
First Online: 3 March 2026
Competing interests
: R.S.M. served as a consultant reviewer for OrcaBio and received an honorarium from Lumanity for providing an expert opinion. E.J.S. serves as a consultant for Cimeio Therapeutics AG, New York Blood Centre, Celaid Therapeutics Inc, Scientific Advisor for Adaptimmune Limited, Navan Technologie, Axio Research, FibroBiologics, is on the Board of Directors/Management for National Marrow Donor Program, and License agreement for Affimed, Takeda, Rege Nexus, and is a speaker for Dava Oncology. K.R. and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical and Affimed GmbH. K.R. participates on the Scientific Advisory Board for Avenge Bio, Virogin Biotech, Navan Technologies, Caribou Biosciences, Bit Bio Limited, Replay Holdings, oNKo Innate, The Alliance for Cancer Gene Therapy (ACGT), Innate Pharma, and Shinobi Therapeutics. K.R. is the scientific founder of Syena.
